Role of matrix metalloproteinase‐9 (MMP‐9) in striatal blood–brain barrier disruption in a 3‐nitropropionic acid model of Huntington's disease
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
J. Duran‐Vilaregut, J. del Valle, G. Manich, A. Camins, M. Pallàs, J. Vilaplana and C. Pelegrí (2011) Neuropathology and Applied Neurobiology37, 525–537 Role of matrix metalloproteinase (MMP)‐9 in striatal blood–brain barrier disruption in a 3‐nitropropionic acid model of Huntington's disease Aims: 3‐Nitropropionic acid (3‐NPA) is a natural toxin that, when administered to experimental animals, reproduces the brain lesions observed in Huntington's disease, which mainly consist of selective neurodegeneration of the striatum. The lesions also include severe alterations to the blood–brain barrier (BBB), which increase its permeability to several substances including blood components and exogenous fluorescent dyes, and the concomitant degradation of some of its constituents such as endothelial cells, tight junction proteins and the basement membrane. We studied here the role of matrix metalloproteinases (MMPs)‐2 and ‐9, also called gelatinases A and B, in the degradation of the BBB in the striatal lesions induced by the systemic administration of 3‐NPA to Sprague‐Dawley rats. Methods: 3‐NPA was intraperitoneally administered at a dose of 20 mg/kg once a day for 3 days. MMPs were studied by means of immunohistochemistry and in situ zymography. Results: In 3‐NPA‐treated rats, MMP‐9 was present in most of the degraded blood vessels in the injured striatum, while it was absent in vessels from non‐injured tissue. In the same animals, MMP‐2 staining was barely detected close to degraded blood vessels. The combination of MMP‐9 immunostaining, in situ zymography and inhibitory studies of MMP‐9 confirmed that net gelatinolytic activity detected in the degraded striatal blood vessels could be attributed almost exclusively to the active form of MMP‐9. Conclusion: Our results highlight the prominent role of MMP‐9 in BBB disruption in the striatal injured areas of this experimental model of Huntington's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NeuN, a neuronal specific nuclear protein in vertebratesxs
Mullen, R. J., Buck, C. R., & Smith, A. M. (1992) · Development · doi:10.1242/dev.116.1.201 · Cited by 2,351
Bush, T. G., Puvanachandra, N., Horner, C. H., Polito, A., Ostenfeld, T., Svendsen, C. N., Mucke, L., Johnson, M. H., & Sofroniew, M. V. (1999) · Neuron · doi:10.1016/s0896-6273(00)80781-3 · Cited by 1,116
Yang, Y., Estrada, E. Y., Thompson, J. F., Liu, W., & Rosenberg, G. A. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600375 · Cited by 1,060
Asahi, M., Wang, X., Mori, T., Sumii, T., Jung, J.-C., Moskowitz, M. A., Fini, M. E., & Lo, E. H. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-19-07724.2001 · Cited by 1,004
Blood–brain Barrier: Structural Components and Function Under Physiologic and Pathologic Conditions
Persidsky, Y., Ramirez, S. H., Haorah, J., & Kanmogne, G. D. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-006-9025-3 · Cited by 922
Role of Microglia in Central Nervous System Infections
Rock, R. B., Gekker, G., Hu, S., Sheng, W. S., Cheeran, M., Lokensgard, J. R., & Peterson, P. K. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.4.942-964.2004 · Cited by 723
Matrix metalloproteinases and their multiple roles in neurodegenerative diseases
Rosenberg, G. A. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70016-x · Cited by 594
Metalloproteinases: Mediators of Pathology and Regeneration in the CNS
Yong, V. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1807 · Cited by 582
Cited by
MMP‐9 in translation: from molecule to brain physiology, pathology, and therapy
Vafadari, B., Salamian, A., & Kaczmarek, L. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13415 · Cited by 382
Zymography methods for visualizing hydrolytic enzymes
Vandooren, J., Geurts, N., Martens, E., Van den Steen, P. E., & Opdenakker, G. (2013) · Nature Methods · doi:10.1038/nmeth.2371 · Cited by 320
Factors controlling permeability of the blood–brain barrier
Almutairi, M. M. A., Gong, C., Xu, Y. G., Chang, Y., & Shi, H. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2050-8 · Cited by 306
Brkic, M., Balusu, S., Libert, C., & Vandenbroucke, R. E. (2015) · Mediators of Inflammation · doi:10.1155/2015/620581 · Cited by 205
“Other evidence for involvement of MMP-9 in HD comes from the 3-nitropropionic acid animal model of the disease [79].”
BackgroundRivera, S., García-González, L., Khrestchatisky, M., & Baranger, K. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03178-2 · Cited by 111
Metadata
- Authors
- Duran‐Vilaregut, J., del Valle, J., Manich, G., Camins, A., Pallàs, M., Vilaplana, J., & Pelegrí, C.
- Venue
- Neuropathology and Applied Neurobiology
- Publisher
- Wiley
- Published
- 2011-07-13
- Volume
- 37
- Issue
- 5
- Pages
- 525-537
- ISSN
- 0305-1846 (ISSN-L)
- 1365-2990
- OpenAlex
- W1821062265
- Cited by
- 53
- References
- 8
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of matrix metalloproteinase‐9 (MMP‐9) in striatal blood–brain barrier disruption in a 3‐nitropropionic acid model of Huntington's disease. https://app.cochat.ai/papers/10.1111/j.1365-2990.2010.01157.x
- The paper
- Duran‐Vilaregut, J., del Valle, J., Manich, G., Camins, A., Pallàs, M., Vilaplana, J., & Pelegrí, C. (2011). Role of matrix metalloproteinase‐9 (MMP‐9) in striatal blood–brain barrier disruption in a 3‐nitropropionic acid model of Huntington's disease. Neuropathology and Applied Neurobiology. https://doi.org/10.1111/j.1365-2990.2010.01157.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.